Cell Therapeutics, Spectrum Form Joint Venture

Xconomy Seattle — 

Seattle-based Cell Therapeutics announced it has teamed up with Spectrum Pharmaceuticals of Irvine, CA, to create a 50-50 joint venture, RIT Oncology, to commercialize and develop the cancer drug Zevalin. The drug for non-Hodgkin’s lymphoma, which Xconomy has written about extensively, will be marketed in the U.S.

By posting a comment, you agree to our terms and conditions.

Comments are closed.